Skip to main content

Table 4 Adverse events reported by the patients during pradigastat treatment

From: Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome

Adverse events, n (%)

Treatment period 1

Treatment period 2

Treatment period 3

Total (n = 6)

Pradigastat 20 mg (n = 6)

Pradigastat 40 mg (n = 6)

Pradigastat 10 mg (n = 4)

Diarrhea

4 (66.7)

5 (83.3)

3 (75.0)

6 (100.0)

Abdominal pain

3 (50.0)

2 (33.3)

1 (25.0)

4 (66.7)

Nausea

0 (0.0)

2 (33.3)

1 (25.0)

2 (33.3)

Flatulence

2 (33.3)

2 (33.3)

3 (75.0)

4 (66.7)

Abdominal pain upper

2 (33.3)

2 (33.3)

0 (0.0)

2 (33.3)

Fecal incontinence

1 (16.7)

0 (0.0)

0 (0.0)

1 (16.7)

Abdominal distension

1 (16.7)

0 (0.0)

0 (0.0)

1 (16.7)

Dizziness

0 (0.0)

1 (16.7)

0 (0.0)

1 (16.7)

Insomnia

1 (16.7)

1 (16.7)

0 (0.0)

1 (16.7)

Dyspepsia

1 (16.7)

0 (0.0)

0 (0.0)

1 (16.7)

Influenza

1 (16.7)

1 (16.7)

0 (0.0)

2 (33.3)

  1. A patient with multiple occurrences of an adverse event is counted only once in a category during each treatment period.